Insulet Corporation
$ 201.49
1.86%
14 Apr - close price
- Market Cap 14,184,060,000 USD
- Current Price $ 201.49
- High / Low $ 203.59 / 198.80
- Stock P/E 57.73
- Book Value 21.53
- EPS 3.49
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.18 %
- 52 Week High 354.88
- 52 Week Low 194.61
About
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
Analyst Target Price
$340.26
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-18 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-20 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-11-02 | 2023-08-08 | 2023-05-04 |
| Reported EPS | 1.44 | 1.24 | 1.17 | 1.02 | 1.15 | 0.9 | 0.55 | 0.73 | 1.4 | 0.71 | 0.38 | 0.23 |
| Estimated EPS | 1.46 | 1.14 | 0.92 | 0.79 | 1.021 | 0.76 | 0.56 | 0.39 | 0.66 | 0.4 | 0.26 | 0.11 |
| Surprise | -0.02 | 0.1 | 0.25 | 0.23 | 0.129 | 0.14 | -0.01 | 0.34 | 0.74 | 0.31 | 0.12 | 0.12 |
| Surprise Percentage | -1.3699% | 8.7719% | 27.1739% | 29.1139% | 12.6347% | 18.4211% | -1.7857% | 87.1795% | 112.1212% | 77.5% | 46.1538% | 109.0909% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.14 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PODD
2026-04-15 02:57:26
Dexcom Inc. is a leader in continuous glucose monitoring (CGM) systems, with its technology addressing the needs of over 38 million Americans with diabetes. The company's business model relies on recurring revenue from sensor replacements and is expanding its market to include Type 2 diabetics and non-diabetics interested in metabolic health. Despite competition, Dexcom maintains a strong competitive edge due to superior accuracy, strategic partnerships, and a focus on innovation and market expansion in the US and English-speaking countries.
2026-04-14 23:18:24
Dexcom Inc. is a leader in continuous glucose monitoring (CGM) technology, providing real-time blood sugar data for diabetes patients, positioning it as a key investment in healthcare innovation. The company's dominance is driven by its recurring revenue model from sensor replacements, advanced G7 system, and strategic expansion into international markets and broader patient segments like non-insulin users. Despite competition and potential risks like reimbursement changes, analyst views highlight Dexcom's strong economic moat and long-term growth potential due to its innovation, market share, and clinical evidence of cost savings.
2026-04-14 20:38:32
Evercore ISI has reiterated an Outperform rating for Insulet Corp. (PODD) but reduced its price target from $340 to $240, still indicating over 21% upside. This revision follows broader adjustments in the medical technologies sector and a recent medical device correction for Omnipod 5 batches due to a manufacturing flaw affecting 1.5% of annual production. Despite this, management has implemented quality control changes, and the company continues to focus on its insulin management systems.
2026-04-14 20:38:18
Pomerantz LLP is investigating potential securities fraud claims against Insulet Corporation (NASDAQ: PODD) after the company disclosed a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods due to a manufacturing issue. This announcement led to a 6.88% drop in Insulet's stock price on March 13, 2026. The law firm is encouraging affected investors to contact them regarding participation in a potential class action lawsuit.
2026-04-14 16:08:39
RBC Capital has reiterated its "Buy" rating on Insulet (PODD.US) but has adjusted its price target downwards to $325. This indicates a continued positive outlook on the stock, despite a reduction in the anticipated future value.
2026-04-12 18:38:19
The article indicates that analysts project a significant 75% upside for Insulet Corporation (PODD) even though its share price momentum has been weak. This suggests a strong belief among analysts in the company's future performance and potential for growth, despite current market sentiment.
